CY1111613T1 - Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv - Google Patents

Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv

Info

Publication number
CY1111613T1
CY1111613T1 CY20101100937T CY101100937T CY1111613T1 CY 1111613 T1 CY1111613 T1 CY 1111613T1 CY 20101100937 T CY20101100937 T CY 20101100937T CY 101100937 T CY101100937 T CY 101100937T CY 1111613 T1 CY1111613 T1 CY 1111613T1
Authority
CY
Cyprus
Prior art keywords
treatment
methods
hiv infection
agents
compound
Prior art date
Application number
CY20101100937T
Other languages
Greek (el)
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111613(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1111613T1 publication Critical patent/CY1111613T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20101100937T 2004-03-24 2010-10-20 Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv CY1111613T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
EP05723932A EP1732604B1 (en) 2004-03-24 2005-03-01 Methods of treating hiv infection

Publications (1)

Publication Number Publication Date
CY1111613T1 true CY1111613T1 (el) 2015-10-07

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100937T CY1111613T1 (el) 2004-03-24 2010-10-20 Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC7.html)
CN (1) CN1956720B (cg-RX-API-DMAC7.html)
AR (1) AR048333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC7.html)
CA (1) CA2561146C (cg-RX-API-DMAC7.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC7.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20104925B (cg-RX-API-DMAC7.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC7.html)
IL (1) IL178141A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC7.html)
MY (1) MY144318A (cg-RX-API-DMAC7.html)
NO (1) NO337116B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549778A (cg-RX-API-DMAC7.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC7.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC7.html)
PT (1) PT1732604E (cg-RX-API-DMAC7.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC7.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347184B (cg-RX-API-DMAC7.html)
UA (1) UA88463C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS54055B1 (sr) 2011-01-31 2015-10-30 Bristol-Myers Squibb Company POSTUPCI ZA PRIPREMU JEDINJENJA PROLEKA INHIBITORA VEZIVANJA HIV-a I INTERMEDIJERA
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
EP3313412A4 (en) 2015-06-23 2019-01-16 CytoDyn Inc. INHIBITION OF CCL5 LIGAND BINDING AT CCR5 RECEPTOR AND CHANGING CCR5 / CCL5 AXIS SIGNALING IN INFUSION, CANCER, AUTOIMMUNE AND OTHER DISORDERS
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
WO2003049690A2 (en) * 2001-12-12 2003-06-19 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN102153540A (zh) * 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
EP1732604A2 (en) 2006-12-20
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
NZ549778A (en) 2010-09-30
DE602005022420D1 (de) 2010-09-02
DK1732604T3 (da) 2010-11-15
JP4847441B2 (ja) 2011-12-28
UA88463C2 (ru) 2009-10-26
WO2005102392A3 (en) 2006-07-20
CN1956720B (zh) 2010-12-15
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
US7776863B2 (en) 2010-08-17
RU2006137555A (ru) 2008-04-27
IL178141A0 (en) 2006-12-31
ES2347801T3 (es) 2010-11-04
NO20064547L (no) 2006-10-06
IL178141A (en) 2010-11-30
PL1732604T3 (pl) 2010-12-31
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
AU2005235116B2 (en) 2011-03-31
CN1956720A (zh) 2007-05-02
RU2367439C2 (ru) 2009-09-20
PT1732604E (pt) 2010-09-24
EP1732604B1 (en) 2010-07-21
BRPI0509140A (pt) 2007-09-04
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
CA2561146C (en) 2013-12-24
NO337116B1 (no) 2016-01-25
AR048333A1 (es) 2006-04-19
TW200538117A (en) 2005-12-01
KR20070011322A (ko) 2007-01-24
CA2561146A1 (en) 2005-11-03
ZA200607959B (en) 2008-06-25
WO2005102392A2 (en) 2005-11-03
KR101158140B1 (ko) 2012-06-19
ATE474602T1 (de) 2010-08-15
IN2012DN06436A (cg-RX-API-DMAC7.html) 2015-10-09
TWI347184B (en) 2011-08-21

Similar Documents

Publication Publication Date Title
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
CY1110665T1 (el) Αναστολεις hiv ιντεγκρασης
CY1110266T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
CY1107419T1 (el) Προφαρμακα αντι-ιικων μεσων απο πιπεραζινη και υποκατεστημενη πιπεριδινη
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1118936T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για την αγωγη ή την προληψη νοσου σχετιζομενης με οξαλικο
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
SE0302304D0 (sv) Novel compounds
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
WO2006034001A3 (en) Methods of treating hiv infection
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα